M Miller

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Physiology

Disorders

Anatomy

Cytotoxic T-Lymphocytes

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Mukamal Kenneth J; Wee Christina C; Miller Matthew
BMI and rates of suicide in the United States: an ecological analysis.
Svarovskaia Evguenia S; Feng Joy Y; Margot Nicolas A; Myrick Florence; Goodman Derrick; Ly John K; White Kirsten L; Kutty Nilima; Wang Ruth; Borroto-Esoda Katyna; Miller Michael D
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.
Murray Robert J; Lewis Fraser I; Miller Michael D; Brown Andrew J Leigh
Genetic basis of variation in tenofovir drug susceptibility in HIV-1.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of M Miller (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Mukamal Kenneth J; Wee Christina C; Miller Matthew
BMI and rates of suicide in the United States: an ecological analysis.
Obesity (Silver Spring, Md.) 2009;17(10):1946-50.
2008: Svarovskaia Evguenia S; Feng Joy Y; Margot Nicolas A; Myrick Florence; Goodman Derrick; Ly John K; White Kirsten L; Kutty Nilima; Wang Ruth; Borroto-Esoda Katyna; Miller Michael D
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.
Journal of acquired immune deficiency syndromes (1999) 2008;48(4):428-36.
2008: Murray Robert J; Lewis Fraser I; Miller Michael D; Brown Andrew J Leigh
Genetic basis of variation in tenofovir drug susceptibility in HIV-1.
AIDS (London, England) 2008;22(10):1113-23.
2008: Winters Bart; Montaner Julio; Harrigan P Richard; Gazzard Brian; Pozniak Anton; Miller Michael D; Emery Sean; van Leth Frank; Robinson Patrick; Baxter John D; Perez-Elias Marie; Castor Delivette; Hammer Scott; Rinehart Alex; Vermeiren Hans; Van Craenenbroeck Elke; Bacheler Lee
Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.
Journal of acquired immune deficiency syndromes (1999) 2008;48(1):26-34.
2008: Pandrea Ivona; Ribeiro Ruy M; Gautam Rajeev; Gaufin Thaidra; Pattison Melissa; Barnes Mary; Monjure Christopher; Stoulig Crystal; Dufour Jason; Cyprian Wayne; Silvestri Guido; Miller Michael D; Perelson Alan S; Apetrei Cristian
Simian immunodeficiency virus SIVagm dynamics in African green monkeys.
Journal of virology 2008;82(7):3713-24.
2008: Gordon Shari N; Dunham Richard M; Engram Jessica C; Estes Jacob; Wang Zichun; Klatt Nichole R; Paiardini Mirko; Pandrea Ivona V; Apetrei Cristian; Sodora Donald L; Lee Ha Youn; Haase Ashley T; Miller Michael D; Kaur Amitinder; Staprans Silvija I; Perelson Alan S; Feinberg Mark B; Silvestri Guido
Short-lived infected cells support virus replication in sooty mangabeys naturally infected with simian immunodeficiency virus: implications for AIDS pathogenesis.
Journal of virology 2008;82(7):3725-35.
2008: Vela Jennifer E; Miller Michael D; Rhodes Gerald R; Ray Adrian S
Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools.
Antiviral therapy 2008;13(6):789-97.
2008: McColl Damian J; Chappey Colombe; Parkin Neil T; Miller Michael D
Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
Antiviral therapy 2008;13(2):189-97.
2007: Miller Michael
Resistance to integrase inhibitors.
Journal of HIV therapy 2007;12(4):101.
2007: Borroto-Esoda Katyna; Miller Michael D; Arterburn Sarah
Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials.
Journal of hepatology 2007;47(4):492-8.
2007: Zhu Yuao; Curtis Maria; Snow-Lampart Andrea; Yang Huiling; Delaney William; Miller Michael D; Borroto-Esoda Katyna
In vitro drug susceptibility analysis of hepatitis B virus clinical quasispecies populations.
Journal of clinical microbiology 2007;45(10):3335-41.
2007: Svarovskaia Evguenia S; Margot Nicolas A; Bae Andrew S; Waters Joshua M; Goodman Derrick; Zhong Lijie; Borroto-Esoda Katyna; Miller Michael D
Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.
Journal of acquired immune deficiency syndromes (1999) 2007;46(2):174-80.
2007: Dominguez Stephanie; Ghosn Jade; Peytavin Gilles; Izzedine Hassan; Wirden Marc; Ktorza Nadine; Miller Michael; Aubron-Olivier Camille; Trylesinski Aldo; Calvez Vincent; Deray Gilbert; Katlama Christine
Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
Journal of medical virology 2007;79(2):105-10.
2007: Ly John K; Margot Nicolas A; MacArthur Holly L; Hung Magdeleine; Miller Michael D; White Kirsten L
The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.
Antiviral chemistry & chemotherapy 2007;18(6):307-16.
2007: Borroto-Esoda Katyna; Parkin Neil; Miller Michael D
A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.
Antiviral chemistry & chemotherapy 2007;18(5):297-300.
2007: Qi Xiaoping; Xiong Shelly; Yang Huiling; Miller Michael; Delaney William E
In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
Antiviral therapy 2007;12(3):355-62.
2006: Margot N A; Waters J M; Miller M D
In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.
Antimicrobial agents and chemotherapy 2006;50(12):4087-95.
2006: Svarovskaia Evguenia S; Moser Michael J; Bae Andrew S; Prudent James R; Miller Michael D; Borroto-Esoda Katyna
MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples.
Journal of clinical microbiology 2006;44(11):4237-41.
2006: Delaney William E; Ray Adrian S; Yang Huiling; Qi Xiaoping; Xiong Shelly; Zhu Yuao; Miller Michael D
Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.
Antimicrobial agents and chemotherapy 2006;50(7):2471-7.
2006: Borroto-Esoda Katyna; Vela Jennifer E; Myrick Florence; Ray Adrian S; Miller Michael D
In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.
Antiviral therapy 2006;11(3):377-84.
2005: Delaunay Christophe; Brun-Vézinet Françoise; Landman Roland; Collin Gilles; Peytavin Gilles; Trylesinski Aldo; Flandre Philippe; Miller Michael; Descamps Diane
Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
Journal of virology 2005;79(15):9572-8.
2005: Havlir Diane V; Koelsch Kersten K; Strain Matthew C; Margot Nicolas; Lu Biao; Ignacio Caroline C; Miller Michael D; Wong Joseph K;
Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
The Journal of infectious diseases 2005;191(7):1164-8.
2005: Weber Jan; Chakraborty Bikram; Weberova Jitka; Miller Michael D; Quiñones-Mateu Miguel E
Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.
Journal of clinical microbiology 2005;43(3):1395-400.
2005: Yang Huiling; Qi Xiaoping; Sabogal Alex; Miller Michael; Xiong Shelly; Delaney William E
Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV.
Antiviral therapy 2005;10(5):625-33.
2005: Ray Adrian S; Myrick Florence; Vela Jennifer E; Olson Loren Y; Eisenberg Eugene J; Borroto-Esodo Katyna; Miller Michael D; Fridland Arnold
Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.
Antiviral therapy 2005;10(3):451-7.
2005: Margot Nicolas A; Miller Michael D
In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1.
Antiviral therapy 2005;10(2):343-8.
2004: Shen Ling; Shen Yun; Huang Dan; Qiu Liyou; Sehgal Prabhat; Du George Z; Miller Michael D; Letvin Norman L; Chen Zheng W
Development of Vgamma2Vdelta2+ T cell responses during active mycobacterial coinfection of simian immunodeficiency virus-infected macaques requires control of viral infection and immune competence of CD4+ T cells.
The Journal of infectious diseases 2004;190(8):1438-47.
2004: Brun-Vézinet Françoise; Costagliola Dominique; Khaled Mounir Ait; Calvez Vincent; Clavel François; Clotet Bonaventura; Haubrich Richard; Kempf Dale; King Marty; Kuritzkes Daniel; Lanier Randall; Miller Michael; Miller Veronica; Phillips Andrews; Pillay Deenan; Schapiro Jonathan; Scott Janna; Shafer Robert; Zazzi Maurizio; Zolopa Andrew; DeGruttola Victor
Clinically validated genotype analysis: guiding principles and statistical concerns.
Antiviral therapy 2004;9(4):465-78.
2004: Masquelier Bernard; Tamalet Catherine; Montès Brigitte; Descamps Diane; Peytavin Gilles; Bocket Laurence; Wirden Marc; Izopet Jacques; Schneider Véronique; Ferré Virginie; Ruffault Annick; Palmer Pierre; Trylesinski Aldo; Miller Michael; Brun-Vézinet Françoise; Costagliola Dominique;
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.
Antiviral therapy 2004;9(3):315-23.
2004: Magierowska Magdalena; Bernardin Flavien; Garg Seema; Staprans Silvija; Miller Michael D; Van Rompay Koen K A; Delwart Eric L
Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques.
Journal of virology 2004;78(5):2434-44.
2004: Deval Jérôme; White Kirsten L; Miller Michael D; Parkin Neil T; Courcambeck Jérôme; Halfon Philippe; Selmi Boulbaba; Boretto Joëlle; Canard Bruno
Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations.
The Journal of biological chemistry 2004;279(1):509-16.
2003: Westland Chris; Delaney William; Yang Huiling; Chen Shan-Shan; Marcellin Patrick; Hadziyannis Stephanos; Gish Robert; Fry John; Brosgart Carol; Gibbs Craig; Miller Michael; Xiong Shelly
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.
Gastroenterology 2003;125(1):107-16.
2003: McColl Damian J; Miller Michael D
The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1.
The Journal of antimicrobial chemotherapy 2003;51(2):219-23.
2002: Harrigan P R; Miller M D; McKenna P; Brumme Z L; Larder B A
Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.
Antimicrobial agents and chemotherapy 2002;46(4):1067-72.
2001: Shen Y; Shen L; Sehgal P; Zhou D; Simon M; Miller M; Enimi E A; Henckler B; Chalifoux L; Sehgal N; Gastron M; Letvin N L; Chen Z W
Antiretroviral agents restore Mycobacterium-specific T-cell immune responses and facilitate controlling a fatal tuberculosis-like disease in Macaques coinfected with simian immunodeficiency virus and Mycobacterium bovis BCG.
Journal of virology 2001;75(18):8690-6.
2001: Palmer S; Margot N; Gilbert H; Shaw N; Buckheit R; Miller M
Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance.
AIDS research and human retroviruses 2001;17(12):1167-73.
2001: Naeger L K; Miller M D
Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: is it all figured out?
Current opinion in investigational drugs (London, England : 2000) 2001;2(3):335-9.
2000: Shulman N S; Zolopa A R; Passaro D J; Murlidharan U; Israelski D M; Brosgart C L; Miller M D; Van Doren S; Shafer R W; Katzenstein D A
Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response.
Journal of acquired immune deficiency syndromes (1999) 2000;23(3):221-6.
2000: Van Rompay K K; Miller M D; Marthas M L; Margot N A; Dailey P J; Canfield D R; Tarara R P; Cherrington J M; Aguirre N L; Bischofberger N; Pedersen N C
Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.
Journal of virology 2000;74(4):1767-74.
1997: Miller M D; Warmerdam M T; Ferrell S S; Benitez R; Greene W C
Intravirion generation of the C-terminal core domain of HIV-1 Nef by the HIV-1 protease is insufficient to enhance viral infectivity.
Virology 1997;234(2):215-25.
1996: Geleziunas R; Miller M D; Greene W C
Unraveling the function of HIV type 1 Nef.
AIDS research and human retroviruses 1996;12(17):1579-82.
1996: Miller M D; Greene W C
Is the Nef protein of HIV-1 required for pathogenesis?
Trends in microbiology 1996;4(5):171-2; discussion 173.
1995: Goldsmith M A; Warmerdam M T; Atchison R E; Miller M D; Greene W C
Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef.
Journal of virology 1995;69(7):4112-21.
1995: Miller M D; Warmerdam M T; Page K A; Feinberg M B; Greene W C
Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry.
Journal of virology 1995;69(1):579-84.
1994: Miller M D; Feinberg M B; Greene W C
The HIV-1 nef gene acts as a positive viral infectivity factor.
Trends in microbiology 1994;2(8):294-8.
1994: Miller M D; Warmerdam M T; Gaston I; Greene W C; Feinberg M B
The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages.
The Journal of experimental medicine 1994;179(1):101-13.
1994: Miller M D; Sheridan R P; Kearsley S K; Underwood D J
Advances in automated docking applied to human immunodeficiency virus type 1 protease.
Methods in enzymology 1994;241():354-70.
1993: Letvin N L; Miller M D; Shen L; Chen Z W; Yasutomi Y
Simian immunodeficiency virus-specific cytotoxic T lymphocytes in rhesus monkeys: characterization and vaccine induction.
Seminars in immunology 1993;5(3):215-23.
1992: Miller M D; Gould-Fogerite S; Shen L; Woods R M; Koenig S; Mannino R J; Letvin N L
Vaccination of rhesus monkeys with synthetic peptide in a fusogenic proteoliposome elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes.
The Journal of experimental medicine 1992;176(6):1739-44.
1992: Chen Z W; Shen L; Miller M D; Ghim S H; Hughes A L; Letvin N L
Cytotoxic T lymphocytes do not appear to select for mutations in an immunodominant epitope of simian immunodeficiency virus gag.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(12):4060-6.
1992: Yamamoto H; Ringler D J; Miller M D; Yasutomi Y; Hasunuma T; Letvin N L
Simian immunodeficiency virus-specific cytotoxic T lymphocytes are present in the AIDS-associated skin rash in rhesus monkeys.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(2):728-34.
1991: Reimann K A; Snyder G B; Chalifoux L V; Waite B C; Miller M D; Yamamoto H; Spertini O; Letvin N L
An activated CD8+ lymphocyte appears in lymph nodes of rhesus monkeys early after infection with simian immunodeficiency virus.
The Journal of clinical investigation 1991;88(4):1113-20.
1991: Miller M D; Yamamoto H; Hughes A L; Watkins D I; Letvin N L
Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys.
Journal of immunology (Baltimore, Md. : 1950) 1991;147(1):320-9.
1991: Shen L; Chen Z W; Miller M D; Stallard V; Mazzara G P; Panicali D L; Letvin N L
Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes.
Science (New York, N.Y.) 1991;252(5004):440-3.
1990: Yamamoto H; Miller M D; Watkins D I; Snyder G B; Chase N E; Mazzara G P; Gritz L; Panicali D L; Letvin N L
Two distinct lymphocyte populations mediate simian immunodeficiency virus envelope-specific target cell lysis.
Journal of immunology (Baltimore, Md. : 1950) 1990;145(11):3740-6.
1990: Yamamoto H; Miller M D; Tsubota H; Watkins D I; Mazzara G P; Stallard V; Panicali D L; Aldovini A; Young R A; Letvin N L
Studies of cloned simian immunodeficiency virus-specific T lymphocytes. gag-specific cytotoxic T lymphocytes exhibit a restricted epitope specificity.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(9):3385-91.
1990: Miller M D; Lord C I; Stallard V; Mazzara G P; Letvin N L
The gag-specific cytotoxic T lymphocytes in rhesus monkeys infected with the simian immunodeficiency virus of macaques.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(1):122-8.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

M Miller

Research Profile (preview)

Chemicals & Drugs

Living Beings

Physiology

Disorders

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of M Miller (preview)

All Publications